Hematopoietic Cell Transplantation in Acute Myeloid Leukemia

Antonio M. Jimenez, Stefan O. Ciurea

Research output: Chapter in Book/Report/Conference proceedingChapter


This chapter discusses issues that arise when considering stem cell transplantation (SCT) for acute myeloid leukemia (AML) patients. Cytogenetics at diagnosis is the most important prognostic factor, and aggressive consolidation strategies such as allogeneic SCT (allo-SCT) in first remission (CR1) in high-risk cytogenetic patients are beneficial. Age should not be an absolute contraindication to proceed with allo-SCT when pursuing a curative approach. It is important to consider performance status and comorbid conditions, rather than age alone, when evaluating transplant candidates. Multiple retrospective series have shown that survival was significantly improved when allogeneic transplantation was compared to nontransplant alternatives such as high-dose cytarabine and targeted therapy. There is no consensus on the optimal management of AML relapse following transplant, and outcomes for patients who relapse following allo-SCT are dismal.

Original languageEnglish (US)
Title of host publicationCancer Consult
Subtitle of host publicationExpertise for Clinical Practice
Number of pages7
ISBN (Electronic)9781118589199
ISBN (Print)9781118589212
StatePublished - Jun 20 2014
Externally publishedYes


  • AML relapse
  • Acute myeloid leukemia (AML)
  • Allogeneic stem cell transplantation (allo-SCT)
  • First remission (CR1)
  • Hematopoietic stem cell transplantation (HSCT)
  • High-risk cytogenetic patients

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Hematopoietic Cell Transplantation in Acute Myeloid Leukemia'. Together they form a unique fingerprint.

Cite this